AI-IMMUNOLOGY™: Evaxion's pioneering AI-Immunology™ platform accelerates fast and effective vaccine target discovery, design, and development. Using the power of AI, our platform simulates the human immune system and generates predictive models to identify and develop personalized and other next-generation immunotherapies for patients.

The power of AI-Immunology™ in vaccine target discovery, design and development

clinical trials confirm predictive capabilities and link to outcomes

0hrs

to complete target discovery

fewer targets needs testing

0%+

on average cheaper target discovery versus reverse vaccinology

vaccine target hit-rate

different modalities (protein, DNA, mRNA, peptides)

different diseases can be addressed

BACTERIAL INFECTIOUS DISEASES

EDEN™ is a proprietary AI-Immunology™ model that rapidly identifies those antigens that will trigger a robust protective immune response against almost any bacterial infectious disease. EDEN™ is fully AI-driven and designed to identify vaccine candidates faster and at a lower cost than current state-of-the-art methods. With EDEN™, we take a novel approach to vaccine development with the aim of combatting the rising global issue of antibiotic resistance.

Learn more

R&D Day 2024

Evaxion Overview - Setting the Scene

Watch Christian Kanstrup, CEO, give an overview of Evaxion's unique differentiators and how we intend to utilize these to save and improve patients' lives.

AI-Immunology™ - A Leading AI Platform

Watch Andreas Holm Mattsson, Chief AI Officer and Founder of Evaxion, provide an introduction to the company's history and the driving force behind the development of our core AI-Immunology™ platform. In this video, you will gain new insights into the scalable modular architecture of AI-Immunology™ and how it has enabled the company to expand to different therapeutic areas.

EvaxMHC 4.0 - A Cutting-Edge AI Building Block

Watch Michael Schantz Klausen, Scientist and ML Engineer at Evaxion, give a presentation on EvaxMHC - one of the core building blocks of our AI-Immunology™ platform. In his presentation, Michael takes you through the intricacies of peptide-MHC interactions and how EvaxMHC novel deep-learning algorithms achieve best-in-class performance.

Watch Andreas Holm Mattsson, Chief AI Officer and Founder of Evaxion, present the EDEN™ model and its strides towards addressing pressing global needs such as growing antimicrobial resistance. In his presentation, Andreas walks you through the unique feature recognition capabilities of EDEN™ and how these allow for faster and cheaper vaccine discovery.

Watch Pantherna's Ansgar Santel, Head of Translational Research, and Evaxion's Stine Friis, Director of Immuno-Oncology and Preclinical Development, present how the collaboration between the two companies can enhance the delivery of cancer-specific antigens with CCL19 as APCt unit.

RAVEN™ - Model for Uncovering Unique Cross-Protective T-Cell Antigens

Watch Michael Schantz Klausen, Scientist and ML Engineer at Evaxion, give a presentation on RAVEN™, a model from the AI-Immunology™ platform trained to design T-cell hotspot vaccines. In his presentation, Michael explores the various applications of RAVEN™ under different vaccine strategies and the advantages it provide for rapid pathogen outbreak response.

PIONEER™ - Validated Model for Designing Personalized Neoantigen Vaccines

Watch Thomas Trolle, Director of Bioinformatics & AI/ML at Evaxion, present the PIONEER™ model and how it has led the parading shift from traditional one-fits-all approaches into tailored cancer vaccines. In his presentation, Thomas explains how PIONEER™ predicts high-quiality neoantigens by unraveling disease mechanisms, and showcases validating data deriving from Evaxion's clinical trials.

AI-DEEP™ - Model for Predicting Responses to Cancer CPI Immunotherapy

Watch Christian Garde, Scientific Director of Bioinformatics at Evaxion, give a presentation on our responder model, AI-DEEP™. In his presentation, Christian highlights the current need for better guidance in patients' checkpoint inhibitor (CPI) treatment and how Evaxion aims to address this by leveraging AI-Immunology™ existing predicting capabilities.

Addressing difficult to treat cancers with AI-Immunology™

Watch Jens Kringelum, VP of AI & Innovation at Evaxion, give a presentation on how Evaxion is addressing difficult to treat cancers with AI-Immunology™.